Caszyme

Pioneering Gene Editing with AI: Caszyme's Blend of Innovation and Expertise🧬 At Caszyme, we are applying #AI to enhance the development of precise and efficient #CRISPR-based tools. 🔬 Our scientist, Dr. Renatas Krasauskas, shares his perspective on where AI fits within the broader landscape of gene editing research. AI is proving to be a valuable tool in this field, but as Dr. Krasauskas notes, it cannot replace the need for hands-on validation: ❝Testing all AI-driven solutions - both in silico and in the wet lab is a fundamental part of our process to ensure they meet the highest standards of accuracy and reliability. Only when both are combined, can the use of AI in gene editing contribute to more powerful and effective tools.❞ 👀 Read more in our newsletter and subscribe to get the latest updates: https://lnkd.in/dcnpBsZp #AI #GeneEditing #CRISPR #innovation #Caszyme #Newsletter

It’s been a rewarding week for Caszyme at the #CRISPRMED25 conference! 🌟 Our CEO, Monika Paule, started the week at the Founder’s Breakfast, discussing Caszyme’s journey in the CRISPR field and showcasing our pipeline of gene editing solutions. 🧬 The keynote by #CRISPR pioneer and Caszyme co-founder Prof. Virginijus Siksnys captivated a large audience as he took us through the evolution of CRISPR-Cas systems - from bacterial immunity to transformative genome editing tools that continue to evolve today. 🔎 Our CSO, Giedrius Gasiunas, highlighted the capabilities of #Cas12l in his talk and continued the discussion during the poster sessions, diving deeper into the scientific process behind engineering this compact and potent genome editor. We’re proud to have contributed to the #CRISPRMED25 event, which has brought together the leaders in the CRISPR community. Thanks to CRISPR Medicine News for organizing this insightful gathering, including the early morning fun runs around beautiful Copenhagen! 👏 Let’s stay connected! If you haven’t had the chance to stop by, there’s still time - visit us at Booth #A2! #Caszyme #CRISPR #GeneEditing #Talks #Posters

🌻 Spring is here: Caszyme in Q1 The first quarter of 2025 has been a fantastic one for Caszyme. In this new edition of our #newsletter, we summarize key company developments, and show off recent Caszyme-led advancements in #CRISPR technology, as well as new collaborations and important updates. As ever, we remain focused on innovation and delivering high-quality solutions in gene editing. Read more and subscribe to our newsletter to get the latest updates on Caszyme's developments 🧬

Exciting news! The UNCOVER project has officially launched! 🇱🇹 🇰🇷 🌟 We’re proud to announce our collaboration with Vilniaus universitetas / Vilnius University and nSAGE company on the co-development of an advanced CRISPR-based diagnostics platform for the accurate and rapid detection of infectious diseases. 🔬 🔎 👉 As Caszyme CSO, Giedrius Gasiunas, explains: "To achieve improved sensitivity and specificity of the detection platform, we are going to leverage our deep knowledge in advanced bioinformatics and Cas protein engineering, allowing the systematic optimization of a more robust system." 💡This platform will be versatile, user-friendly, and effective for both human and animal health, as well as easily programable to address a wide range of pathogens and disease biomarkers. 👉 Our CEO, Monika Paule, notes: "Partnerships are the essential link connecting unique expertise to innovative solutions." We’re excited about what lies ahead—and the positive impact this platform could have on global health. 🌟 🔗 Learn more: https://lnkd.in/dN6SM9xi #UNCOVER #Caszyme #Diagnostics #CRISPR

🚀 Caszyme team will be at #CRISPRMED25 in Copenhagen from April 7-11! An exciting week of insightful discussions on CRISPR innovation awaits: 📢 April 8 | 10:00 AM - Our CEO, Monika Paule, will speak at the Founder's breakfast, discussing Caszyme’s capabilities and contribution to CRISPR innovation.   📢 April 8 | 3:00 PM - Prof. Virginijus Siksnys, Caszyme's co-founder, will give a Keynote speech: “CRISPR-Cas: From bacterial immunity towards genome editing and beyond”. 📢 April 9 | 12:35 PM - Our CSO, Giedrius Gasiunas, will present on engineering a potent CRISPR-Cas12l genome editor - an excellent opportunity to catch up on the latest #Cas12l research. 🔬 💬 Meet us at Booth #A2 to chat, or reach out via DM to schedule a dedicated meeting with CEO Monika Paule, Business Development Director Donatas Staniulis, or CSO Giedrius Gasiunas. We look forward to connecting in Copenhagen! 👋 #CRISPR #GenomeEditing #Caszyme #Innovation

The #GlobalInnovationSummit 2025 will take place next week, April 1-2, at the heart of HANNOVER MESSE ✨ As part of the Eureka Academy: Eurostars & Fast Track to EIC Accelerator sessions, our CEO, Monika Paule, will discuss Caszyme’s journey with the #Eurostars project, sharing our experience and its positive impact.💡 🎓 Join us at one of these Eureka Network academy sessions to gain some practical insights: 👉 April 1st at 13:15-14:15 👉 April 2nd at 11:15-12:15 Looking forward to some great conversations! #Eurostars #furthertogether #Innovation #Caszyme 

Last week at the Advanced Therapies Congress, we had the pleasure of connecting with industry leaders to discuss the latest advancements in cell and gene therapies 🔬 🧬 It was a valuable opportunity to showcase Caszyme's work in the CRISPR field and explore potential collaborations. We were also pleased to present Caszyme’s activities at the biotech networking event, "From Pink Soup to Afternoon Tea" ☕, organized by Innovation Agency Lithuania | Global and MedCity. Such events are crucial for building bilateral partnerships and driving innovation across borders💡🌍 🤝 Thank you to everyone we met - it was a pleasure to engage in meaningful conversations. We look forward to continuing the discussions in the future! 🔄 #AdvancedTherapies #GeneEditing #CRISPR #Networking #Caszyme

Join Caszyme at Advanced Therapies 2025 🌟 On March 18-19, Caszyme’s CEO Monika Paule and Business Development Director Donatas Staniulis will be in London for Europe's largest Cell & Gene Therapy event. We're excited to connect and discuss how CRISPR drives innovation and how Caszyme can contribute to developing next-generation therapies 🧬 💡 Let’s meet! 🧬 Come swing by our Booth #56 🧬 Explore our Poster "Unlocking the Transformative Power of CRISPR Gene Editing in Advanced Therapies" 🧬 Reach out to set up a meeting! We look forward to seeing you in London 🌟 #Caszyme #AdvancedTherapies #CRISPR #GeneEditing

Our CEO, Monika Paule, is featured in Citeline Commercial's Scrip Asks series, where she shares her insights on the biopharma industry in 2025 💡 In this latest article, Monika emphasizes the critical role of collaboration in transforming novel technologies into advanced therapies and ensuring their accessibility to patients. 👉 Explore the full feature to gain further insights from industry leaders and experts: https://lnkd.in/dSyX8Mmu #biopharma #biotech #therapies #innovation #geneediting

Our CEO, Monika Paule, will be in San Francisco for the World Agri-Tech Innovation Summit & Future Food-Tech Summit from March 11 to 14! With so many industry leaders gathering together, we are eager to discuss how Caszyme’s expertise in gene editing can contribute to sustainable innovation within the agri-food sector. 🌱🔬 If you’re also attending, we look forward to connecting with you! 📩 Reach out to schedule a meeting with Monika to explore CRISPR technology applications in agriculture and food-tech. #AgriTech #FoodTech #CRISPR #GeneEditing #Innovation #Sustainability